Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Datta, K. Ghoshal, W. Denny, S. Gamage, D. Brooke, Pasit Phiasivongsa, S. Redkar, S. Jacob (2009)A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation.
Cancer research, 69 10
Sabine Hagemann, D. Kuck, C. Stresemann, F. Prinz, B. Brueckner, C. Mund, D. Mumberg, A. Sommer (2012)Antiproliferative Effects of DNA Methyltransferase 3B Depletion Are Not Associated with DNA Demethylation
PLoS ONE, 7
Shikhar Sharma, T. Kelly, Peter Jones (2010)Epigenetics in cancer.
Carcinogenesis, 31 1
Udi Gluschnaider, G. Hidas, G. Cojocaru, V. Yutkin, Y. Ben-Neriah, E. Pikarsky (2010)β-TrCP Inhibition Reduces Prostate Cancer Cell Growth via Upregulation of the Aryl Hydrocarbon Receptor
PLoS ONE, 5
P. Fenaux, G. Mufti, E. Hellstrom-Lindberg, V. Santini, C. Finelli, A. Giagounidis, R. Schoch, N. Gattermann, G. Sanz, A. List, S. Gore, J. Seymour, J. Bennett, J. Byrd, J. Backstrom, L. Zimmerman, D. McKenzie, C. Beach, L. Silverman (2009)Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
The Lancet. Oncology, 10 3
B. Druker, F. Guilhot, S. O’Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. Deininger, R. Silver, J. Goldman, R. Stone, F. Cervantes, A. Hochhaus, B. Powell, J. Gabrilove, P. Rousselot, J. Reiffers, J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J. Nielsen, J. Radich, B. Simonsson, K. Taylor, M. Baccarani, Charlene So, L. Letvak, R. Larson (2006)Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
The New England journal of medicine, 355 23
Jack Cuzick, I. Sestak, S. Pinder, Ian Ellis, Sharon Forsyth, N. Bundred, John Forbes, H. Bishop, Ian Fentiman, W. George (2013)Lancet Oncol 10
D. Kuck, T. Caulfield, F. Lyko, J. Medina‐Franco (2010)Nanaomycin A Selectively Inhibits DNMT3B and Reactivates Silenced Tumor Suppressor Genes in Human Cancer Cells
Molecular Cancer Therapeutics, 9
(2013)2013)Selective enhancing effect of early mitotic inhibitor 1 depletion on the sensitivity of doxorubicin or X-ray treatment in human cancer cells
J. Maris (2010)Recent advances in neuroblastoma.
The New England journal of medicine, 362 23
Jessica Charlet, M. Schnekenburger, K. Brown, M. Diederich (2012)DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs.
Biochemical pharmacology, 83 7
B. Brueckner, Regine Boy, P. Siedlecki, Tanja Musch, H. Kliem, P. Zielenkiewicz, S. Suhai, M. Wiessler, F. Lyko (2005)Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases.
Cancer research, 65 14
B. Maier, S. Wendt, J. Vanselow, T. Wallach, S. Reischl, S. Oehmke, A. Schlosser, A. Kramer (2009)A large-scale functional RNAi screen reveals a role for CK2 in the mammalian circadian clock.
Genes & development, 23 6
R. George, J. Lahti, P. Adamson, Kejin Zhu, D. Finkelstein, A. Ingle, J. Reid, M. Krailo, D. Neuberg, S. Blaney, L. Diller (2010)Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group study
Pediatric Blood & Cancer, 55
B. Spänkuch, S. Heim, E. Kurunci-Csacsko, C. Lindenau, Juping Yuan, M. Kaufmann, K. Strebhardt (2006)Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Cancer research, 66 11
G. Takemura, H. Fujiwara (2007)Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management.
Progress in cardiovascular diseases, 49 5
S. Fulda, W. Lutz, M. Schwab, K. Debatin (1999)MycN sensitizes neuroblastoma cells for drug-induced apoptosis
Y. Qiu, B. Mirkin, R. Dwivedi (2005)Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells.
Cancer detection and prevention, 29 5
D. Goldschneider, E. Horvilleur, L. Plassa, M. Guillaud-Bataille, K. Million, Evelyne Wittmer-Dupret, G. Danglot, H. Thé, J. Bénard, E. May, S. Douc-Rasy (2006)Expression of C-terminal deleted p53 isoforms in neuroblastoma
Nucleic Acids Research, 34
Zhih-Cherng Chen, Li-Jen Chen, Juei-Tang Cheng (2013)Doxorubicin-Induced Cardiac Toxicity Is Mediated by Lowering of Peroxisome Proliferator-Activated Receptor δ Expression in Rats
PPAR Research, 2013
N. Cheung, M. Dyer (2013)Neuroblastoma: developmental biology, cancer genomics and immunotherapy
Nature Reviews Cancer, 13
M. Schlabach, Ji Luo, N. Solimini, G. Hu, Qikai Xu, Mamie Li, Zhenming Zhao, A. Smogorzewska, M. Sowa, Xiaolu Ang, T. Westbrook, A. Liang, K. Chang, J. Hackett, J. Harper, G. Hannon, S. Elledge (2008)Cancer Proliferation Gene Discovery Through Functional Genomics
Lüder Wiebusch, C. Hagemeier (2010)p53- and p21-dependent premature APC/C–Cdh1 activation in G2 is part of the long-term response to genotoxic stress
Weigang Tang, Y. Li, Duonan Yu, A. Thomas-Tikhonenko, V. Spiegelman, S. Fuchs (2005)Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells.
Cancer research, 65 5
C. Riccardi, I. Nicoletti (2006)Analysis of apoptosis by propidium iodide staining and flow cytometry
Nature Protocols, 1
M Esteller (2008)Epigenetics in cancer
N Engl J Med, 358
Stefan Schiesser, T. Pfaffeneder, K. Sadeghian, Benjamin Hackner, B. Steigenberger, A. Schröder, J. Steinbacher, Gengo Kashiwazaki, G. Höfner, K. Wanner, C. Ochsenfeld, T. Carell (2013)Deamination, oxidation, and C-C bond cleavage reactivity of 5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxycytosine.
Journal of the American Chemical Society, 135 39
P. García-Domínguez, C. Dell'Aversana, R. Álvarez, L. Altucci, A. Lera (2013)Synthetic approaches to DNMT inhibitor SGI-1027 and effects on the U937 leukemia cell line.
Bioorganic & medicinal chemistry letters, 23 6
V. Hegde, R. McFarlane, E. Taylor, C. Price (1996)The genetics of the repair of 5-azacytidine-mediated DNA damage in the fission yeast
Molecular Genetics and Genomics, 251
B Spänkuch-Schmitt, J Bereiter-Hahn, M Kaufmann, K Strebhardt (2002)Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells
J Natl Cancer Inst, 94
V Hegde, RJ McFarlane, EM Taylor, C Price (1996)The genetics of the repair of 5-azacytidine-mediated DNA damage in the fission yeast Schizosaccharomyces pombe
Mol Gen Genet, 251
Weigang Tang, Ying Li, Duonan Yu, A. Thomas-Tikhonenko, V. Spiegelman, S. Fuchs (2005)Targeting β-Transducin Repeat–Containing Protein E3 Ubiquitin Ligase Augments the Effects of Antitumor Drugs on Breast Cancer Cells
Cancer Research, 65
Y. Qiu, B. Mirkin, R. Dwivedi (2002)Differential expression of DNA-methyltransferases in drug resistant murine neuroblastoma cells.
Cancer detection and prevention, 26 6
Natsumi Shimizu, N. Nakajima, Takaaki Tsunematsu, I. Ogawa, H. Kawai, R. Hirayama, A. Fujimori, A. Yamada, R. Okayasu, N. Ishimaru, T. Takata, Y. Kudo (2013)Selective Enhancing Effect of Early Mitotic Inhibitor 1 (Emi1) Depletion on the Sensitivity of Doxorubicin or X-ray Treatment in Human Cancer Cells*
The Journal of Biological Chemistry, 288
Y. Machida, Anindya Dutta (2007)The APC/C inhibitor, Emi1, is essential for prevention of rereplication.
Genes & development, 21 2
Birgit Spänkuch-Schmitt, J. Bereiter-Hahn, M. Kaufmann, K. Strebhardt (2002)Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells.
Journal of the National Cancer Institute, 94 24
After extensive research on radiochemotherapy, 5-year survival rates of children with high risk neuroblastoma still do not exceed 50%, owing to adverse side-effects exemplified by doxorubicin-induced cardiomyopathy. A promising new approach is the combination of conventional therapies with specific modulation of cell signaling pathways promoting therapeutic resistance, such as inhibition of aberrant kinase activity or re-expression of silenced tumor suppressor genes by means of chromatin remodeling. In this regard, we established a system that allows to identify potential drug targets as well as to validate respective candidate inhibitors in high-risk neuroblastoma model cell lines. Cell culture, drug exposure, shRNA-mediated knockdown and phenotype analysis are integrated into an efficient and versatile single well-based protocol. By utilizing this system, we assessed RG108, SGI-1027 and nanaomycin A, three novel DNA methyltransferase inhibitors that have not been tested in neuroblastoma cell lines so far, for their potential of synergistic anti-tumor activity in combination with doxorubicin. We found that, similarly to azacytidine, SGI-1027 and nanaomycin A mediate synergistic growth inhibition with doxorubicin independently of N-Myc status. However, they display high cytotoxicity but lack global DNA demethylation activity. Secondly, we conducted a lentiviral shRNA screen of F-box proteins, key regulators of protein stability, and identified Fbxw11/β-TrCP2 as well as Fbxo5/Emi1 as potential therapeutic targets in neuroblastoma. These results complement existing studies and underline the reliability and versatility of our single well-based protocol.
Targeted Oncology – Springer Journals
Published: Jan 6, 2015
Access the full text.
Sign up today, get DeepDyve free for 14 days.